P2Y12 adenosine diphosphate receptor (P2Y12 receptor (P2Y12R))

The P2Y12 adenosine diphosphate receptor is a G protein-coupled receptor (GPCR) expressed primarily on platelets, playing a central role in ADP-mediated platelet activation, aggregation, and stabilization of thrombus formation[1][3][4]. This receptor is a critical amplifier of platelet responses and contributes to hemostasis, thrombosis, and pathologic clot formation within blood vessels[1][4][3]. It couples to Gi proteins, mediating inhibition of adenylyl cyclase and facilitating dense granule secretion, fibrinogen receptor activation, and release of procoagulant factors[1][5]. Genetic defects in this receptor are associated with mild-to-moderate bleeding tendencies[3]. The P2Y12 receptor is the molecular target of several clinically important antiplatelet drugs, including thienopyridines (clopidogrel, prasugrel, ticlopidine) and reversible antagonists (ticagrelor, cangrelor, elinogrel), which are widely used in the prevention and treatment of cardiovascular diseases such as coronary artery disease, acute coronary syndrome, and in the setting of percutaneous coronary intervention[2][8][6]. Beyond hemostatic function, P2Y12 has emerging roles in inflammation and cancer biology, including potential impact on tumor growth and metastasis by modulating platelet-tumor cell interactions[3][5][6]. Blockade of this receptor is a cornerstone of modern antithrombotic therapy but entails an increased risk of bleeding and inter-individual variability in drug effectiveness, especially with prodrugs such as clopidogrel[3][4].

Other names

P2Y12 purinoceptorplatelet ADP receptorP2TP2Y(ADP)P2Y(cyc)P2T(AC)

Irreversible inhibition (clopidogrel, prasugrel, ticlopidine: require metabolic activation); Reversible direct inhibition (ticagrelor, cangrelor, elinogrel); Competitive inhibition at ADP binding site